ALT5 Sigma (NASDAQ:AIFC – Get Free Report) released its quarterly earnings results on Monday. The company reported ($2.14) EPS for the quarter, FiscalAI reports. The business had revenue of $4.71 million for the quarter. ALT5 Sigma had a negative return on equity of 50.52% and a negative net margin of 1,386.90%.
ALT5 Sigma Price Performance
NASDAQ:AIFC opened at $0.91 on Tuesday. The company has a current ratio of 0.57, a quick ratio of 0.57 and a debt-to-equity ratio of 0.01. ALT5 Sigma has a 52-week low of $0.73 and a 52-week high of $10.95. The stock has a 50-day simple moving average of $1.10 and a 200 day simple moving average of $1.50.
Wall Street Analyst Weigh In
Separately, Wall Street Zen lowered ALT5 Sigma from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 18th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the company. Balyasny Asset Management L.P. bought a new position in ALT5 Sigma in the fourth quarter valued at approximately $26,000. Arete Wealth Advisors LLC acquired a new position in ALT5 Sigma in the 3rd quarter valued at $28,000. Profund Advisors LLC acquired a new position in ALT5 Sigma in the 3rd quarter valued at $28,000. Victory Capital Management Inc. acquired a new position in ALT5 Sigma in the 3rd quarter valued at $33,000. Finally, First Citizens Bank & Trust Co. acquired a new position in ALT5 Sigma in the 3rd quarter valued at $35,000. 6.27% of the stock is currently owned by institutional investors.
About ALT5 Sigma
ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.
Featured Stories
- Five stocks we like better than ALT5 Sigma
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for ALT5 Sigma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALT5 Sigma and related companies with MarketBeat.com's FREE daily email newsletter.
